Infliximab: a treatment option for ulcerative pyoderma gangrenosum.
As a tumor necrosis factor-alpha antagonist, infliximab is approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis and Crohn's disease. Infliximab has been used to treat a variety of dermatological diseases. Among these is pyoderma gangrenosum (PG), an un...
| Publicado en: | Wounds: A Compendium of Clinical Research & Practice Vol. 15; no. 2; pp. 49 - 54 |
|---|---|
| Autores principales: | , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
HMP Global
2003 Feb Supplement
|
| Acceso en línea: | Ver este registro en EBSCOhost |